|
Post by selluwud on Mar 20, 2015 18:40:56 GMT
Bought some at $2.53 this morning. Glad I did. Now...where to sell? Good question. Let it ride with stops under it? take profit soon? Long term? Got to make a plan Stan.
|
|
|
Post by Yelk on Mar 20, 2015 20:27:46 GMT
This is going much higher very soon. Retail pushing for $3 list to nasdaq, results PR and continuation enrollment next week! I am very happy I added 10% to my position here yesterday at a negative close. I only have about 50% of a full position so sort of sad but will look for an opportunity to add more. My recommendation as someone who has been in and out of this stock would be to sell the day of or morning after enrollment continued news or at least take profit.
The way this stock works is all hype and go and when its over everyone is like : "What now?"
HOWEVER - If Jessi's results are good I won't be taking an profits.
|
|
|
Post by Yelk on Mar 20, 2015 20:38:27 GMT
Was just reading she moves her leg on own. This is fantastic news. I need to do more research on what a placebo response looks like but either way it looks like scaffold helps...
|
|
|
Post by Yelk on Mar 21, 2015 1:59:04 GMT
Looking forward to next week with this. You know for sure when NVIV does their PR it will have positive news about Jessi and her leg movement. Continued enrollment with efficacy in fully paralyzed patients 2/2. Once again with these catalysts and up-listing I am doing my best to not sound like a pumper here lol.One mistake I learned from a few weeks ago is looking at this stock in my portfolio and expecting it go up every day (which it did) if you haven't already learned the lesson stocks just don't or shouldn't do that - especially in biotech .
|
|
|
Post by forthefuture on Mar 21, 2015 2:29:34 GMT
Also looking for the official PR, though I wonder if she was seen in an official office visit after her leg started moving, or if she did it at home, in which case I doubt NVIV would officially PR it. Either way, expecting them to open up enrollment next week which should drive a positive move. I'm hoping the cult following behind this stock really gets it moving. The one X factor is Frank Reynolds. The guys still has millions of shares to sell I'm sure so there's going to be some selling pressure as long as that guy is around.
|
|
|
Post by Yelk on Mar 21, 2015 5:22:03 GMT
Also looking for the official PR, though I wonder if she was seen in an official office visit after her leg started moving, or if she did it at home, in which case I doubt NVIV would officially PR it. Either way, expecting them to open up enrollment next week which should drive a positive move. I'm hoping the cult following behind this stock really gets it moving. The one X factor is Frank Reynolds. The guys still has millions of shares to sell I'm sure so there's going to be some selling pressure as long as that guy is around. I'm not concerned about Frank at all. He lost beneficial ownership a long time ago signifying a limited amount of million shares. Also this thing is trading 2-3 million shares on positive days (with no news)... Even if he dumped 10 million shares over a week this would absorb it IMO. But I don't think he will. He had his fun - articles that wrote about Frank and why the company was down at 50 cents knew he couldn't stop it going to $3 and it will be the same to $6 and $18 and on. I'd also like to point out we aren't even on Nasdaq. The real investors aren't even trading this thing and it can do 3 million shares on a day without news with a market cap this high -> just saying. Some key points from Jason Napodano: If Jordan is stating that he is getting some feeling back at one month, we are very excited to see his progress at 3, 6, and 12 months.This is the exact time frame Jessi got some feeling in legs and this trial is just for safety. Accordingly, we recommend the stock for long-term investors. We anticipate raising our odds of success if patient No. 2 shows similar impressive gains to the ones made by patient No. 1, Jordan Fallis.
"I play golf, a lot. InVivo just stood on the first tee and ripped one 300 yards down the center of the fairway. Are they a professional or a 20 handicapper that just got lucky? We will have to wait for the next shot to get a definitive answer, but if we’re picking partners based on the drive – I’m with them.
InVivo’s basic market capitalization is $169 million. We think peak sales of the NSS, device alone under HUD, is $600 million. The market triples in size under a PMA to $1.8 billion. If the company can strike an alliance with a stem cell supplier and figure out how to seed the NSS with neural-spinal stem cells, then the market opens up from approximately 12,000 acute patients per year to some 300,000 chronic patients. That’s a 25-fold increase."That was written when the stock was $1.50 so more like a conservative 10X upside if all goes well. While paralysis isn't a huge market like stroke it does draw a lot of attention and the scaffold seems to work very, very well. I know monkeys aren't humans but the fact that 46/46 or however many they tested all were paralyzed and all were restored shows consistency and Jessi has just proven that to me. Even if this device does not restore you to full or regain feeling for everyone looking at the science it is beneficial for healing either way and appears to be quite safe. This is my #3 stock I am most excited for in 2015. RVX is first then ATHX and CTH is easily fourth. Also Jessi was in the hospital when she regained feeling which is why she said and I quote: "They told me I am regaining..." She was readmitted to rehab after some sort of allergic reaction (not scaffold related). At least this is what I am assuming. The reason I assume further that it will be on PR is NVIV has been excellent at updating Jordan in a few hours after every news that hits even on their company webcast slides, which I can say is more than many companies do. Yes Frank is a risk however I think there are a few other risks as well. -OTC -Stock is on hot air as the base of this fast incline was created on light volume on Jordan miracle boy results. I got in around $1.45 but the volume at the point was non-existent I think we need to be wary of the risks here, however if Jessi shows similar results to Jordan I think we could be off to races even if the next 3 patients don't show major efficacy. This is after all safety trial...
|
|
|
Post by selluwud on Mar 23, 2015 13:46:36 GMT
For those in this stock what we have coming up in the next 7-14 days: Patient 2 data Possible up list The volume has been huge and I can see a possible 30-50% upside near the end of March if everything goes very well. Nice move over 3.00 this AM, when is the patient data due?
|
|
|
Post by Yelk on Mar 23, 2015 20:05:24 GMT
For those in this stock what we have coming up in the next 7-14 days: Patient 2 data Possible up list The volume has been huge and I can see a possible 30-50% upside near the end of March if everything goes very well. Nice move over 3.00 this AM, when is the patient data due? Should be this week. Possibly Mon/Tue next week.
|
|
|
Post by forthefuture on Mar 23, 2015 20:15:06 GMT
Expect PR out this week
|
|
|
Post by Yelk on Mar 23, 2015 23:41:29 GMT
The recent MEIP incident has heightened my awareness of to overdone data, but the thing I like about NVIV is you get to hear from the patients themselves. Really it's hard to fail this way... Furthermore you could say the same thing with CUR and the blogs however CUR we only heard from the patients who did well so didn't prove much. Here we have live daily updates from 100% of the patient population and it has been nothing but good news.
|
|
|
Post by selluwud on Mar 24, 2015 12:12:31 GMT
Reverse split announced 1 for 4 to prepare for uplist. finance.yahoo.com/news/invivo-therapeutics-announces-reverse-stock-120000176.htmlInVivo Therapeutics Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ Business Wire InVivo Therapeutics Holdings Corp. 9 minutes ago CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV) today announced that its Board of Directors has approved a 1-for-4 reverse stock split of its issued and outstanding common stock in preparation for its planned uplisting to the NASDAQ Capital Market. The company anticipates the reverse stock split to become effective and its common stock to begin trading on a post-split basis at the open of trading on April 8, 2015, contingent upon approval from the Financial Industry Regulatory Authority (FINRA). “The execution of this reverse split represents an important step in achieving an essential corporate objective – uplisting to a national securities exchange,” said Mark Perrin, Chief Executive Officer and Chairman of the Board. “Becoming NASDAQ-listed allows companies to attract a broader range of institutional investors and to increase share liquidity. I, together with the rest of the Board, am pleased to be moving forward towards such an important goal in our corporate evolution. This important step in changing our capitalization is yet another key element in our transformation.” At the effective time of the reverse stock split, every four shares of issued and outstanding common stock will be converted into one newly issued share of common stock. Any fractional shares resulting from the reverse stock split will be rounded up the nearest whole share. A new CUSIP will be assigned to the company’s common stock after the reverse stock split becomes effective. The reverse stock split is intended to fulfill InVivo’s requirements for listing to the NASDAQ Capital Market since the requirements include that a company’s common stock must maintain a minimum closing price of $3.00 for at least five trading days. There can be no assurance that NASDAQ will approve the company’s application for listing after the reverse stock split is completed. Additional discussion of Reverse Splits can be found at “CEO’s Perspective” on the InVivo Therapeutics website: www.invivotherapeutics.com/about-invivo/ceo-perspective/.
|
|
|
Post by JHam on Mar 24, 2015 12:50:06 GMT
Reverse split announced 1 for 4 to prepare for uplist. finance.yahoo.com/news/invivo-therapeutics-announces-reverse-stock-120000176.htmlInVivo Therapeutics Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ Business Wire InVivo Therapeutics Holdings Corp. 9 minutes ago CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV) today announced that its Board of Directors has approved a 1-for-4 reverse stock split of its issued and outstanding common stock in preparation for its planned uplisting to the NASDAQ Capital Market. The company anticipates the reverse stock split to become effective and its common stock to begin trading on a post-split basis at the open of trading on April 8, 2015, contingent upon approval from the Financial Industry Regulatory Authority (FINRA). “The execution of this reverse split represents an important step in achieving an essential corporate objective – uplisting to a national securities exchange,” said Mark Perrin, Chief Executive Officer and Chairman of the Board. “Becoming NASDAQ-listed allows companies to attract a broader range of institutional investors and to increase share liquidity. I, together with the rest of the Board, am pleased to be moving forward towards such an important goal in our corporate evolution. This important step in changing our capitalization is yet another key element in our transformation.” At the effective time of the reverse stock split, every four shares of issued and outstanding common stock will be converted into one newly issued share of common stock. Any fractional shares resulting from the reverse stock split will be rounded up the nearest whole share. A new CUSIP will be assigned to the company’s common stock after the reverse stock split becomes effective. The reverse stock split is intended to fulfill InVivo’s requirements for listing to the NASDAQ Capital Market since the requirements include that a company’s common stock must maintain a minimum closing price of $3.00 for at least five trading days. There can be no assurance that NASDAQ will approve the company’s application for listing after the reverse stock split is completed. Additional discussion of Reverse Splits can be found at “CEO’s Perspective” on the InVivo Therapeutics website: www.invivotherapeutics.com/about-invivo/ceo-perspective/. Big news. Also probably not bad news. Good that they are splitting the authorized in proportion to the outstanding shares as well. They must feel that they are going to have good data to report.
|
|
|
Post by JHam on Mar 24, 2015 12:55:34 GMT
|
|
|
Post by forthefuture on Mar 24, 2015 14:50:21 GMT
Buying. Still expecting PR this week.
|
|
|
Post by selluwud on Mar 24, 2015 15:32:14 GMT
I wanted to sell premarket while my profit percentage was higher and wait for a re-entry, but I am just holding through the uplist unless something changes.
|
|
|
Post by Yelk on Mar 24, 2015 19:36:20 GMT
I bought on that -13% dip and sold at -5%. I was like no way lol. Still holding a core of about 60% position here. May add today.
|
|
|
Post by Yelk on Mar 27, 2015 4:27:43 GMT
Opened enrollment here now with pretty pathetic volume for the news. I guess it was so expected by this time nobody cared . I am happy the way this stock has held up with the down sector and announcement of reverse split. Hoping for higher here, but may see some consolidation around $3 or below for a bit. Still looking for PR on Jessi...
|
|
|
Post by Yelk on Mar 28, 2015 3:43:01 GMT
New SA article by Jason Napodano. He sounds more pumpy in this article than I have ever read but he has a point: "This is truly astonishing and an enormous improvement in such a short time frame. To put things into perspective, a 1999 analysis by Mario et al found that 10% to 15% of those with initial complete AIS-A injuries converted to incomplete injuries at 12-month follow-up. Only 2% will regain strength below the injury level. Based on initial data from both Jordan and Jesi, InVivo is now "2 for 2" in terms of returning both sensory and motor function to two patients previously classified as AIS-A at less than 90 days post-injury. The probability that InVivo "got unlucky," with both patients having spontaneous recovery, is less than 1%."
Catalysts in the next few weeks are possible uplist and Jessi updates. Late April or rather early May we get 90 day Jessi update. Also we can expect anytime enrollment of next patients as it is now open. Also Jordon 6 month data mid April... loaded up here. Read the article here: seekingalpha.com/article/3034526-invivo-revolutionizing-spinal-cord-injury
|
|
|
Post by Yelk on Apr 3, 2015 3:19:38 GMT
Jessi is making amazing progress. New video today on hands and knees...
Current Catalysts:
~Uplist Early April ~Jordon 6 month PR Mid April ~Jessi 3 month PR Late April ~Enrollment open for next 3 patients at any time ~Announce stem cell partner Later 2015
Reverse split coming soon. The price will be volatile and will most likely gain some ground I'll be looking to add.
|
|
|
Post by forthefuture on Apr 3, 2015 4:26:52 GMT
Jessi is making amazing progress. New video today on hands and knees... Current Catalysts: ~Uplist Early April ~Jordon 6 month PR Mid April ~Jessi 3 month PR Late April ~Enrollment open for next 3 patients at any time ~Announce stem cell partner Later 2015 Reverse split coming soon. The price will be volatile and will most likely gain some ground I'll be looking to add. Def lots going on. One thing I found going through the NVIV website was the claim that most gray matter injury occurs within 24 hours within the injury. Pt 2 had to wait 2 days to stabilize before scaffold implantation so I wouldn't expect to see her improve as far as pt 1. Looks like she's improving though, so we'll see how far she goes!
|
|